For inquiries or customized services, please reach us at pr@pharmaceutical-era.com
Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery...
Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, highlighted preclinical findings from an...
Bruker Corporation announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized...
CS Analytical (CSA), doing business as Raw Material Analytical (RMA), a cGMP laboratory dedicated to advancing product quality and patient safety, today announced that it is set to offer analytical...
VectorY Therapeutics (“VectorY”), a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, today announced €74.5 million ($83.5 million) in new...
ProBio, a global contract research, development, and manufacturing organization announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean...
Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance.
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with...
Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, announced its telehealth...
UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated...
Avanzanite Bioscience B.V. a European pharmaceutical company focused on rare diseases, announced the conclusion of an exclusive licensing agreement with Montreal-based company Cordex Biologics, an ExCellThera...
Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and...